Addressing the opening session of the
Committee for Orphan Medicinal Products (COMP), Minister for Social Dialogue,
Consumer Affairs and Civil Liberties Helena Dalli lauded the Committee’s
invaluable contribution in enhancing and facilitating the development of
innovative medicines for rare, low prevalence, and complex diseases and
Minister Dalli said that the achievement
of COMP can be summarised by more than 1800 positive opinions for orphan
medicinal product designation adopted from the 2,700 applications that have
been reviewed since the year 2000. Some 60% of designated orphan medicines are
intended for paediatric use.
Dalli described the committee as an
excellent example of how the European medicines Agency has succeeded to pool
national expertise for the benefit of patients throughout the entire European
“The EU’s orphan legislation offer
incentives for the development and marketing of drugs to treat, prevent, or
diagnose rare conditions and have been essential in stimulating research and
development of new orphan medicines for patients”, stated Minister Dalli.
The COMP meeting forms part of a series of
twenty-two meetings being hosted as part of the Maltese Presidency, related to
activities of the European Medicines Regulatory Network by the Malta Medicines
It is also being held simultaneously with a
workshop on integrating research and healthcare for rare diseases, organised by
the European Organisation for Rare Diseases (EURORDIS).